

Sialorrhoea - Pipeline Insight, 2021

<https://marketpublishers.com/r/S7DD152B9454EN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: S7DD152B9454EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Sialorrhoea – Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Sialorrhoea Understanding

Sialorrhoea: Overview

Sialorrhea, drooling or excessive salivation is a common problem in neurologically impaired children and in adults who have Parkinson's disease or have had a stroke. It is most commonly caused by poor oral and facial muscle control. Sialorrhea can lead to significant physical and psychosocial complications, including perioral chapping, dehydration, infection, foul odor, stigmatization, and increased dependency and level of care, all of which can create an additional burden for these medically complicated patients. Sialorrhea usually is caused by neuromuscular dysfunction, hypersecretion, sensory dysfunction, or anatomic (motor) dysfunction. The most common cause is neuromuscular dysfunction. Anterior sialorrhea is diagnosed by the observation of excessive drooling. Posterior sialorrhea can be suggested by the history of choking and repeated pneumonias. Treatment for Sialorrhea range from conservative (i.e.,

observation, postural changes, biofeedback) to more aggressive measures such as medication, radiation, and surgical therapy.

'Sialorrhoea - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sialorrhoea pipeline landscape is provided which includes the disease overview and Sialorrhoea treatment guidelines. The assessment part of the report embraces, in depth Sialorrhoea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sialorrhoea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sialorrhoea R&D. The therapies under development are focused on novel approaches to treat/improve Sialorrhoea.

Sialorrhoea Emerging Drugs Chapters

This segment of the Sialorrhoea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sialorrhoea Emerging Drugs

NT0502: Aytu BioPharma

NT0502 (N-desethyloxybutynin) is an oral, once- or twice-daily potential treatment to reduce chronic sialorrhea in patients with neurological and other conditions associated with drooling and excessive salivation. In December 2020, Aytu BioScience and Neos Therapeutics announced that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction. In March 2021, Aytu BioScience announced close of merger with Neos

Therapeutics. . NT0502 is currently in Phase 1 clinical development for treatment of chronic sialorrhea.

Further product details are provided in the report

Sialorrhoea: Therapeutic Assessment

This segment of the report provides insights about the different Sialorrhoea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sialorrhoea

There are approx. 3+ key companies which are developing the therapies for Sialorrhoea. The companies which have their Sialorrhoea drug candidates in the most advanced stage, i.e. Phase II include, Orient pharma.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Sialorrhoea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sialorrhoea: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sialorrhoea therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sialorrhoea drugs.

Sialorrhoea Report Insights

Sialorrhoea Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Sialorrhoea Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Sialorrhoea drugs?

How many Sialorrhoea drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sialorrhoea?

What are the key collaborations (Industry–Industry, Industry–Academia),

Mergers and acquisitions, licensing activities related to the Sialorrhoea therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Sialorrhoea and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Sialorrhoea: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Sialorrhoea – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Sialorrhoea companies' collaborations, Licensing, Acquisition -Deal Value Trends

Sialorrhoea Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Mid Stage Products (Phase II)

Comparative Analysis

OC oral solution: Orient pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I)

Comparative Analysis

NT0502: Aytu BioPharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical stage products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Sialorrhoea Key Companies

Sialorrhoea Key Products

Sialorrhoea- Unmet Needs

Sialorrhoea- Market Drivers and Barriers

Sialorrhoea- Future Perspectives and Conclusion

Sialorrhoea Analyst Views

Sialorrhoea Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Sialorrhoea

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Sialorrhoea
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Sialorrhoea - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/S7DD152B9454EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S7DD152B9454EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970